It is indicated for patients who have undergone four or more lines of therapy, including treatment with three major types of multiple myeloma medications: an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent. Here, CD38 is linked to plasma cell myeloma.